Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.70 |
| ▸ | EGFR | P00533 | 12/20 | 0.70 |
| ▸ | FLT4 | P35916 | 9/20 | 0.70 |
| ▸ | FGFR1 | P11362 | 8/20 | 0.70 |
| ▸ | FLT1 | P17948 | 8/20 | 0.70 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.69 |
| ▸ | TEK | Q02763 | 4/20 | 0.69 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.69 |
| ▸ | AURKA | O14965 | 3/20 | 0.69 |
| ▸ | AXL | P30530 | 3/20 | 0.59 |
| ▸ | RET | P07949 | 2/20 | 0.58 |
| ▸ | PLK4 | O00444 | 1/20 | 0.58 |
| ▸ | GAK | O14976 | 1/20 | 0.58 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.58 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.58 |
| ▸ | ERN1 | O75460 | 1/20 | 0.58 |
| ▸ | STK10 | O94804 | 1/20 | 0.58 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.58 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4375194 | 0.91 | RET (0.60) | KDREGFRFLT4FGFR1FLT1 | |
| SCHEMBL15084518 | 0.89 | KDR (0.67) | KDREGFRFLT4FGFR1FLT1 | |
| SCHEMBL4419529 | 0.84 | KDR (0.60) | KDREGFRFLT4FGFR1FLT1 | |
| SCHEMBL7214411 | 0.83 | KDR (0.67) | KDREGFRFLT4FGFR1FLT1 | |
| SCHEMBL7867152 | 0.83 | KDR (0.98) | KDREGFRFLT4FGFR1FLT1 | |
| SCHEMBL15084560 | 0.83 | KDR (0.66) | KDREGFRFLT4FGFR1FLT1 | |
| SCHEMBL15084515 | 0.83 | KDR (0.66) | KDREGFRFLT4FGFR1FLT1 | |
| SCHEMBL4375533 | 0.82 | KDR (0.61) | KDREGFRFLT4FGFR1FLT1 | |
| Hydrochloric Acid SCHEMBL7864665 | 0.82 | KDR (1.00) | KDREGFRFLT4FGFR1FLT1 | |
| SCHEMBL5258966 | 0.82 | AURKA (1.00) | KDREGFRFLT4PDGFRBTEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | disclosed |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | STOKES ELAINE S E (GB) | 2012-08-02 | — | — | US | disclosed |
| EP-2050744-A1 | Quinazoline derivatives as angiogenesis inhibitors | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| EP-1528925-B1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| US-7504408-B2 | Quinzoline derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2009-03-17 | — | — | US | disclosed |
| EP-1381599-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-09-24 | — | — | EP | disclosed |
| US-7223756-B2 | Quinazoline compounds with therapeutic use | ASTRAZENECA AB (SE) | 2007-05-29 | — | — | US | disclosed |
| EP-1453492-B1 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2007-01-24 | — | — | EP | disclosed |
| US-7157467-B2 | Administering compound such as 6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-morpholinopropoxy)quinazoline for therapy of an autoimmune disease or medical condition selected from transplant rejection and rheumatoid arthritis | ASTRAZENECA AB (SE) | 2007-01-02 | — | — | US | disclosed |
| US-7141577-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2006-11-28 | — | — | US | disclosed |
| WO-2003045364-A2 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | WO | disclosed |
| EP-1313727-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002030924-A9 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2003-05-22 | — | — | WO | disclosed |
| WO-2002092579-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-21 | — | — | WO | disclosed |
| WO-2002085895-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002030924-A1 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002030926-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002016352-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-02-28 | — | — | WO | disclosed |
| EP-1154774-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000047212-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | VEGFA, FLT1, KDR | KDR 3/4885EGFR 500/4885FLT4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.